ProciseDx Corporation

ProciseDx Corporation develops innovative therapeutic drug monitoring solutions for clinical laboratories, focusing on rapid and accurate testing to support patient management in inflammatory bowel diseases. ProciseDx Corporation specializes in therapeutic drug monitoring (TDM) solutions, providing FDA-cleared tests for Infliximab and Adalimumab. The company is headquartered in San Diego, US, and was recently involved in a major acquisition where Biosynex SA acquired a 57. 33% majority stake in the company on June 13, 2023, for an undisclosed amount.

The company was founded by Larry Mimms and Peter Westlake, both of whom have extensive backgrounds in the diagnostics industry. To date, ProciseDx has secured a total of USD 8. 50 mn across multiple funding rounds, including the latest round of Venture Debt which raised USD 13. 00 mn with participation from investors such as Biosynex SA and Nestle Health Science SA.

ProciseDx specializes in therapeutic drug monitoring (TDM) solutions designed for moderate complexity clinical laboratories. Their flagship offerings include FDA-cleared tests for Infliximab and Adalimumab, which provide gastroenterologists with essential drug concentration information in under five minutes, facilitating timely adjustments in treatment regimens. Utilizing a proprietary trFRET detection system, ProciseDx ensures lab-quality results with rapid turnaround times. Their primary market includes healthcare facilities in the United States and Europe, focusing on enhancing patient management for conditions like Crohn’s disease and ulcerative colitis.

ProciseDx operates on a B2B model, primarily targeting healthcare institutions that require rapid and accurate therapeutic drug monitoring. The company engages in direct partnerships with clinical labs and healthcare providers, generating revenue through service contracts and volume-based pricing structures. This approach may include subscription models or bulk purchasing agreements, although specific pricing details are not disclosed. The emphasis on quick turnaround and precision positions ProciseDx's offerings as premium solutions in the therapeutic monitoring market, reflecting their commitment to innovation and clinical efficacy.

ProciseDx aims to expand its product line with additional tests targeting different therapeutic areas while enhancing its current offerings. The recent acquisition by Biosynex SA is expected to facilitate rapid market penetration and patient outreach. The company plans to increase its presence in European and other global markets by 2024, leveraging the support and resources from Biosynex to accelerate growth and development initiatives.